Trilogy Transcatheter Heart Valve System
JenaValve Technology, Inc. · Decision date May 18, 2026
What did the FDA approve?
FDA records P250024/S001 as a supplement to PMA P250024, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 18, 2026.
FDA approval order statement
approval for the protocol for the Continued Follow-up of the Premarket Cohort post-approval study (PAS)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- May 18, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P250024/S001
- Regulatory pathway
- PMA supplement
- Applicant
- JenaValve Technology, Inc.
- Product code
- NPT
- Decision code
- APPR
- Decision date
- May 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- JenaValve Technology, Inc.
- Product code
- NPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250024. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250024 · Original PMA
Trilogy Transcatheter Heart Valve System
P250024/S001 received
Application receipt date recorded by FDA.
P250024/S002 · Related supplement
Trilogy Transcatheter Heart Valve System
P250024/S001 · FDA decision
Normal 180 Day Track No User Fee
P250024/S003 · Related supplement
Trilogy Transcatheter Heart Valve System
P250024/S006 · Related supplement
Trilogy Transcatheter Heart Valve System
P250024/S005 · Related supplement
Trilogy Transcatheter Heart Valve System
Timeline entries are records held by MedtechLedger for P250024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| JenaValve Technology, Inc. | PMA approval | Mar 17, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S002 | JenaValve Technology, Inc. | PMA supplement | May 18, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S003 | JenaValve Technology, Inc. | PMA supplement | Jul 9, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
JenaValve Technology, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4 Cromwell, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250024/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
